Literature DB >> 2306557

Decreased serum osteocalcin levels in patients with liver cirrhosis.

P Pietschmann1, H Resch, C Müller, W Woloszczuk, R Willvonseder.   

Abstract

Serum levels of osteocalcin (OC) have been found to be a specific biochemical parameter of bone formation. We measured serum levels of osteocalcin, parathyroid hormone (PTH) and 25-hydroxyvitamin D (25(OH)D) in 49 patients with liver cirrhosis, who are known to have an increased prevalence of metabolic bone disease, and a matched control group (n = 35). Serum levels of OC were significantly decreased in the patients with liver cirrhosis when compared to control subjects (P less than 0.001). Serum levels of 25(OH)D were decreased (P less than 0.001), whereas no statistical difference was found between the serum levels of PTH in the patients with liver cirrhosis and those of the controls. In a subgroup of 23 patients with cirrhosis of the liver and 34 control subjects, the bone mineral content (BMC) of the non-dominant forearm was determined by single photon absorptiometry. BMC was significantly lower in the patient with liver cirrhosis than the control subjects (P less than 0.04). Our data demonstrate vitamin D deficiency, decreased bone formation and a decreased BMC in patients with liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306557     DOI: 10.1016/0169-6009(90)90113-t

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  5 in total

1.  Bone disorders in experimentally induced liver disease in growing rats.

Authors:  Viktória Ferencz; Csaba Horváth; Béla Kári; János Gaál; Szilvia Mészáros; Zsuzsanna Wolf; Dalma Hegedus; Andrea Horváth; Anikó Folhoffer; Ferenc Szalay
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Osteodystrophy in patients with chronic hepatitis and liver cirrhosis.

Authors:  K Tsuneoka; Y Tameda; K Takase; T Nakano
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

3.  Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome.

Authors:  Anisha A Gupte; Omaima M Sabek; Daniel Fraga; Laurie J Minze; Satoru K Nishimoto; Joey Z Liu; Solmaz Afshar; Lillian Gaber; Christopher J Lyon; A Osama Gaber; Willa A Hsueh
Journal:  Endocrinology       Date:  2014-10-03       Impact factor: 4.736

Review 4.  Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.

Authors:  Nicola Pugliese; Ivan Arcari; Alessio Aghemo; Andrea G Lania; Ana Lleo; Gherardo Mazziotti
Journal:  World J Gastroenterol       Date:  2022-04-14       Impact factor: 5.374

5.  Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis.

Authors:  Robert Wakolbinger; Christian Muschitz; Jacqueline Wallwitz; Gerd Bodlaj; Xaver Feichtinger; Jakob E Schanda; Heinrich Resch; Andreas Baierl; Peter Pietschmann
Journal:  Wien Klin Wochenschr       Date:  2020-01-07       Impact factor: 1.704

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.